Company Report
Last edited 8 months ago
PerformanceCommunity EngagementCommunity Endorsement
ranked
#9
Performance (60m)
14.4% pa
Followed by
221
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#History
stale
Last edited 8 months ago

Snapshots of Phase 3 progress of Trofinetide for Retts syndrome

Took nearly 3 years for Phase 3 trial to finally complete (Oct 2019 - Feb 2022)

Have done this to understand the timeframe for Phase 3 trials given I'm holding a couple of bios currently undergoing phase 3 at the moment.

24 Feb 2023

0a80562f51e6d95be529525980985fb02d3d1b.png

25 Feb 2022

9768b60448012b822f297cf44a764e35786e62.png

24 feb 2021

ecd15809d8d102451d529eabfe1e3ba5c36fb4.png

6 apr 2020

ce137317536e1c59c9296ec1afe28d0f897ca2.png

Oct 2019

5605e5a0c95238cca2aac0480a8d91486f65d9.png


Phase 3 commencement announcement 31 Oct 2019

f0f5605d63bad697fb4c88193eb32ba9a2843e.png

[held[

#Risks
stale
Added 9 months ago

ACAD dropping on news of ending their drug trials of antipsychotic drug, pimavanserin, for schizophrenia

https://finance.yahoo.com/news/1-acadia-pharmaceuticals-schizophrenia-drug-204620909.html

Although not directly related to NEU, maybe the news is feeding the fear that Arcadia could struggle financially since this was their main product and perhaps impact milestone payments of Daybue.

I haven't looked in the Arcadia financials to confirm any difficulties. But I doubt this will have any impact.

Held

#Risks
stale
Added 12 months ago

Bell potter has a hold on Neuren. Note this was before the trading halt before the SP rocket on 6 dec.

Given BP track record, maybe it is safe to say to ignore these recommendations but use their research to form your own thesis.

de038c30abbe29aa5596e793831c4c30f89061.png

#Bear Case
stale
Added 12 months ago

Don't want to dampen expectations, but I have a bad feeling about this trading halt

Trading halts are not usually used when results are overwhelmingly positive

Some examples where trading halts were not used for positive clinical results/approvals include:

Clarity Pharmaceuticals and the SeCURE PH2 trial update for Cohort 2 (29/11/2023   SECuRE theranostic prostate cancer trial progresses)

Telix Pharmaceuticals Receives TGA approval (02/11/2021   Australian TGA Approves Illuccix for Prostate Cancer Imaging )

Cyclopharm (02/10/2023   Cyclopharm Receives USFDA Approval for Technegas)

On the other hand for trading halts when negative news were received

Rhythm Biosciences - TGA resubmission (01/03/2023   Trading Halt , 06/03/2023   Update to TGA Submission )

Botanix - (26/09/2023   FDA Letter Requires Patient Instruction Update , 25/09/2023   Trading Halt $)

There's probably more, but these are the ones I'm tracking since I have held or held previously

Cross fingers and hope for the best on the Phase II trial results. Try not to have any expectations.

[held]